Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC plus sintilimab as adjuvant therapy after resection for high-risk hepatocellular carcinoma
ChiCTR2300077944Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab and durvalumab + lenvatinib + gemcitabine + cisplatin in hepatocellular carcinoma (HCC), sponsored by Nanjing Drum-Tower Hospital. Started Sep 2023; status: recruiting.
02
Drugs
sintilimabdurvalumab + lenvatinib + gemcitabine + cisplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300077944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077944.